Healthcare
GeneDx Holdings Corp.(WGS)
Live Price
Offline$59.01
+4.59% today
Window Change
+13.50%
Window
May 29, 2026 โ Jun 18, 2026
- Market Cap
- $1.99B
- Revenue Growth
- +40.0%
- EPS Growth
- +62.4%
- Dividend Yield
- 0.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars ยท May 29, 2026 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
GeneDx Holdings Corp. (WGS) is a Healthcare stock with a market cap of $1.99B and listed on NASDAQ. The stock last traded around $59.01 and up 13.5% across the available one-year price window (May 29, 2026 โ Jun 18, 2026). Baseline metrics include revenue growth of +40.0%, EPS growth of +62.4%, a dividend yield of 0.0%. What stands out right now is revenue +40.0%, EPS +62.4%, free cash flow +142.0% with operating margin -2.9% and ROIC -2.7%. Valuation sits in the middle of the pack at price/sales 4.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines WGS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+40.0% vs +7.6% peer median
Operating Margin
Below sector median
-2.9% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 29, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +40.0% and EPS at +62.4%, with operating margin around -2.9%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
WGS
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
WGS Max Drawdown
-7.99%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for WGS and SPY.
Company Overview
GeneDx Holdings Corp.
NASDAQ Global Market
GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.
- Leadership
- Katherine A. Stueland
- IPO Date
- Nov 4, 2020
- Employees
- 1.0k
- Street Address
- North Tower
- Mailing
- Stamford, CT, 06902
- Region
- Stamford, CT, US
- Reporting Currency
- USD
- Investor Line
- 800 298 6470
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 307.4
- Price/Sales
- 4.7
- Price/Book
- 5.9
Growth
- Revenue
- +40.0%
- EPS
- +62.4%
- Free Cash Flow
- +142.0%
Profitability
- Gross Margin
- 68.5%
- Operating Margin
- -2.9%
- Net Margin
- -4.9%
- ROE
- -7.4%
- ROIC
- -2.7%
Balance Sheet
- Debt/Equity
- 0.49
- Current Ratio
- 2.46
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.